Urtoxazumab: Difference between revisions

Revision as of 23:29, 13 November 2011 editThe chemistds (talk \| contribs)Extended confirmed users5,761 edits No ChemSpider ID for this record← Previous edit		Revision as of 23:39, 13 November 2011 edit undoCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_...Next edit →
Line 1:		Line 1:
	{{Drugbox		{{Drugbox
			\| Verifiedfields = changed
	\| verifiedrevid = 450332165		\| verifiedrevid = 450332165
	\| image =		\| image =
Line 36:		Line 37:
	\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}		\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
	\| DrugBank =		\| DrugBank =
			\| ChemSpiderID_Ref = {{chemspidercite\|changed\|chemspider}}
	\| ChemSpiderID = NA		\| ChemSpiderID = NA

Revision as of 23:39, 13 November 2011

Pharmaceutical compound

Urtoxazumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	E. coli Shiga-like toxin II B subunit
Clinical data
ATC code	none
Identifiers
CAS Number	502496-16-4
ChemSpider	NA
Chemical and physical data
Formula	C₆₄₁₄H₉₉₃₄N₁₇₁₈O₂₀₁₀S₄₀
Molar mass	144.6 kDa g·mol
(what is this?) (verify)

Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body.

Human	Efungumab

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab Bamlanivimab (+etesevimab) Bebtelovimab Casirivimab (+imdevimab) Cilgavimab (+tixagevimab) Diridavumab Etesevimab Exbivirumab Foravirumab Imdevimab (+casirivimab) Libivirumab Maftivimab Nirsevimab Odesivimab Pemivibart Rafivirumab Regavirumab Regdanvimab Sevirumab Sipavibart Sotrovimab Suptavumab Tixagevimab (+cilgavimab) Tuvirumab
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab
Humanized	Felvizumab Lenvervimab Motavizumab Palivizumab Suvizumab

Human	Nebacumab Panobacumab Raxibacumab
Mouse	Edobacomab
Chimeric	Pagibaximab
Humanized	Tefibazumab

Human	Actoxumab Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.